Background. To reduce the treatment burden for patients with neovascular age-related macular degeneration (nvAMD), emerging therapies targeting vascular endothelial growth factor (VEGF) are being designed to extend the interval between treatments, thereby minimizing the number of intraocular injections. However, which patients will benefit from longer-acting agents is not clear.

中文翻译：

---

水性蛋白有助于预测新生血管性年龄相关性黄斑变性患者对抗 VEGF 治疗的反应


背景。为了减轻新生血管性年龄相关性黄斑变性（nvAMD）患者的治疗负担，正在设计针对血管内皮生长因子（VEGF）的新兴疗法，以延长治疗间隔，从而最大限度地减少眼内注射次数。然而，哪些患者将从长效药物中受益尚不清楚。